Introduction of NICE’s health technology assessment in UK and enlightenment to the dynamic adjustment of Chinese medical insurance directory_Chinese Journal of Evidence-Based Medicine

Authors：

YAO Jiaqi , ZHOU Ting , GUAN Xin ,  MA Aixia

School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, 211198, P.R.China;

Corresponding?author：

MA Aixia, Email: aixiama73@126.com

Keywords：

Health technology assessment; The national institute for health and care excellence; Health insurance directory selection; Medical insurance directory dynamic adjustment

DOI：

10.7507/1672-2531.201804116

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

This paper used the application of health technology assessment (HTA) in medical insurance directory adjustment as an example, introduced NICE’s HTA in UK from seeking legislative support for HTA, established the system of HTA, improved the process of HTA and increasing awareness of using HTA among decision-maker, and provided suggestions for the development and advancement of HTA in China.

Citation： YAO Jiaqi, ZHOU Ting, GUAN Xin, MA Aixia. Introduction of NICE’s health technology assessment in UK and enlightenment to the dynamic adjustment of Chinese medical insurance directory. Chinese Journal of Evidence-Based Medicine, 2018, 18(9): 984-989. doi: 10.7507/1672-2531.201804116 Copy

1.	OECD. Health expenditure and financing. Available at: http://stats.oecd.org/Index.aspx?DataSetCode.
2.	Babar Z. Pharmaceutical Prices in the 21st Century. Adis, Cham, 2015.
3.	Department of Health. Report of The Triennial Review for The National Institute For Health And Care Excellence. London: Department of Health, 2015.
4.	Department of Health. The Pharmaceutical Price Regulation Scheme Eleventh Report to Parliament. 2012.
5.	NICE. Technology appraisal decisions. Available at: https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance.
6.	Brockis E. A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications, 2016.
7.	NICE. Fast track appraisal. 2017.
8.	NICE. Guide to the methods of technology appraisal, 2013.
9.	NICE. Technology appraisal guidance: Summary of decisions. 2017.
10.	Kaltenthaler E, Papaioannou D, Boland A, et al. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years. Value Health, 2011, 14(8): 1158-1165.
11.	NICE. Guide to the processes of technology appraisal, 2014.
12.	Salas-Vega S, Bertling A, Mossialos E. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. Health Policy, 2016, 120(10): 1104-1114.
13.	NICE. Guide to the technology appraisal and highly specialized technologies appeal process, 2017.
14.	NICE. Guide to the single technology appraisal process, 2012.
15.	Oortwijn W. The role of health technology assessment in selected middle-income countries/regions. Beijing: CNHDRC, 2011.
16.	隋賓艷, 齊雪然. 英國NICE衛生技術評估研究決策轉化機制及對我國的啟示. 中國衛生政策研究, 2015, 8(7): 74-78.
17.	衛生計生委. 關于加強衛生與健康科技成果轉移轉化工作的指導意見. 國衛科教發[2016] 51號, 2016.
18.	醫療保險司. 關于公開征求建立完善基本醫療保險、工傷保險和生育保險藥品目錄動態調整機制有關意見議的通知, 2017.

1. OECD. Health expenditure and financing. Available at: http://stats.oecd.org/Index.aspx?DataSetCode.
2. Babar Z. Pharmaceutical Prices in the 21st Century. Adis, Cham, 2015.
3. Department of Health. Report of The Triennial Review for The National Institute For Health And Care Excellence. London: Department of Health, 2015.
4. Department of Health. The Pharmaceutical Price Regulation Scheme Eleventh Report to Parliament. 2012.
5. NICE. Technology appraisal decisions. Available at: https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance.
6. Brockis E. A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications, 2016.
7. NICE. Fast track appraisal. 2017.
8. NICE. Guide to the methods of technology appraisal, 2013.
9. NICE. Technology appraisal guidance: Summary of decisions. 2017.
10. Kaltenthaler E, Papaioannou D, Boland A, et al. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years. Value Health, 2011, 14(8): 1158-1165.
11. NICE. Guide to the processes of technology appraisal, 2014.
12. Salas-Vega S, Bertling A, Mossialos E. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. Health Policy, 2016, 120(10): 1104-1114.
13. NICE. Guide to the technology appraisal and highly specialized technologies appeal process, 2017.
14. NICE. Guide to the single technology appraisal process, 2012.
15. Oortwijn W. The role of health technology assessment in selected middle-income countries/regions. Beijing: CNHDRC, 2011.
16. 隋賓艷, 齊雪然. 英國NICE衛生技術評估研究決策轉化機制及對我國的啟示. 中國衛生政策研究, 2015, 8(7): 74-78.
17. 衛生計生委. 關于加強衛生與健康科技成果轉移轉化工作的指導意見. 國衛科教發[2016] 51號, 2016.
18. 醫療保險司. 關于公開征求建立完善基本醫療保險、工傷保險和生育保險藥品目錄動態調整機制有關意見議的通知, 2017.

Previous Article
Analysis of different dimensions and related factors of compliance of clinical researchers
Next Article
Establishment of quality criteria for clinical nursing practice guidelines in China

Chinese Journal of Evidence-Based Medicine

Introduction of NICE’s health technology assessment in UK and enlightenment to the dynamic adjustment of Chinese medical insurance directory

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content